Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing 461–480 of 2589 stories
Global Genes announces the launch of RARE-X, a patient-driven initiative aimed at collecting symptom and patient-reported outcome data for rare diseases. This effort seeks to enhance research and understanding of rare conditions through direct patient engagement.
A new NIH-funded study establishes a clear link between severe chronic traumatic encephalopathy (CTE) and increased dementia risk. This research could influence future therapeutic strategies and patient management for individuals with a history of head trauma.
The CDC has launched a new resource page dedicated to providing information for patients and caregivers about preventing falls among older adults. This initiative aims to enhance awareness and support for a vulnerable population.
The CDC has released new guidelines addressing obesity and overweight, emphasizing the need for comprehensive strategies to combat these conditions. The guidelines aim to inform policy decisions and public health initiatives.
The CDC provides updated information on rabies, detailing its transmission, at-risk populations, and prevention strategies. This resource aims to enhance public awareness and safety regarding this preventable disease.
The CDC emphasizes summer swim safety, providing guidelines to prevent accidents and ensure safe swimming practices. This initiative aims to raise awareness among communities about water safety.
The U.S. Department of Health and Human Services rescinded guidance aimed at ensuring nondiscriminatory access to health care at pharmacies. This decision may impact how pharmacies comply with federal civil rights laws regarding access to reproductive health care services.
The FDA has determined the regulatory review period for REZDIFFRA, which is necessary for the patent extension application process. This determination is part of the legal requirements for patent claims related to human drug products.
The CDC is seeking public comment on a proposed data collection project aimed at evaluating support for young breast cancer survivors and those with metastatic breast cancer. This initiative aligns with the agency's goal to reduce public burden and enhance the utility of government information.
FDA has determined the regulatory review period for TRYVIO, which is necessary for a patent extension application. This notice is part of the legal requirements for patent claims related to human drug products.
FDA has determined the regulatory review period for IMAAVY, which is necessary for a patent extension application. This notice is part of the legal requirements for patent claims related to human biological products.
The FDA has determined the regulatory review period for the Symplicity Spyral Renal Denervation System, which is relevant for patent extension applications. This notice is part of the agency's compliance with legal requirements regarding patent claims for medical devices.
FDA has determined the regulatory review period for RYZNEUTA, which is necessary for a patent extension application to the U.S. Patent and Trademark Office. This determination is a procedural step in the patent extension process for this human biological product.
The CDC is seeking public comments on a proposed information collection project aimed at promoting resources for autistic teens and young adults. This initiative aligns with the Paperwork Reduction Act of 1995 and aims to enhance the utility of government information.
FDA has determined the regulatory review period for BIMZELX, which is necessary for a patent extension application. This notice is part of the legal requirements for patent claims related to human biological products.
The FDA has determined the regulatory review period for EXBLIFEP, which is necessary for patent extension applications. This notice is part of the legal requirements for patent claims related to human drug products.
The HHS is undergoing a review under the Paperwork Reduction Act, which may impact data collection processes. Stakeholders should monitor potential changes that could affect reporting requirements.
The HHS is undergoing a review under the Paperwork Reduction Act, which may impact data collection processes. This review is part of ongoing efforts to streamline agency operations.
The CDC is seeking public comment on a proposed information collection project related to the National Network of Sexually Transmitted Diseases Clinical Prevention Training Centers. This initiative aims to enhance data collection while minimizing public burden, as mandated by the Paperwork Reduction Act.
The HHS is undergoing a review under the Paperwork Reduction Act, which may impact data collection processes. Stakeholders should monitor potential changes that could affect reporting requirements.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.